Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GeparOLA
2015-003509-41Phase 2Completed
- Sponsor
- GBG Forschungs
- Start
- May 2016
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of olaparib, paclitaxel, carboplatin, epirubicin and cyclophosphamide in breast cancer (2 arms), sponsored by GBG Forschungs. Primary endpoint: Pathological complete response of breast and lymph nodes. Started May 2016; status: completed.
02
Drugs
olaparibpaclitaxelcarboplatinepirubicincyclophosphamide
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2015-003509-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003509-41.